Form 4: Tenaya Therapeutics Chief Medical Officer Reports Stock Sales to Cover Tax Obligations
SEC Form 4
Chief Medical Officer of Tenaya Therapeutics, Whittemore Tingley, reports selling shares of common stock to cover tax withholding obligations related to vesting restricted stock units.
Summary
- Whittemore Tingley, Chief Medical Officer of Tenaya Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
- On August 16, 2024, Tingley sold 5,803 shares of common stock at a weighted average price of $2.8945 to cover tax obligations related to vesting restricted stock units awarded on February 15, 2023.
- An additional 1,625 shares were sold on the same day at the same price to cover tax obligations related to vesting restricted stock units awarded on February 23, 2024.
- Following these transactions, Tingley beneficially owns 107,106 shares of Tenaya Therapeutics common stock.
- This total includes 63,750 shares issuable upon vesting of restricted stock units and 6,000 shares acquired through the Employee Stock Purchase Plan on June 10, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as the filing reflects routine stock sales for tax purposes, with no indication of a change in the executive's long-term outlook on the company.
Industry Context
Form 4 filings are routine disclosures required by the SEC to provide transparency into the transactions of company insiders. These filings are closely watched by investors to gauge management's sentiment and confidence in the company's prospects.
Comparison to Industry Standards
- Comparing insider trading activity to peers like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics can provide context.
- Similar sales to cover tax obligations are common across the biotech industry after vesting events.
- The volume of shares sold is relatively small compared to the total outstanding shares, suggesting it's primarily for tax purposes rather than a significant change in investment strategy.
Stakeholder Impact
- The stock sales may have a minor, temporary impact on the stock price due to increased selling pressure.
- The transactions do not appear to have a significant impact on other stakeholders, as they are related to routine tax obligations.
Key Dates
| Date | Description |
|---|---|
| February 15, 2023 | Date of restricted stock units awarded, related to the sale of 5,803 shares. |
| February 23, 2024 | Date of restricted stock units awarded, related to the sale of 1,625 shares. |
| June 10, 2024 | Date shares were acquired pursuant to the Tenaya Therapeutics, Inc. 2021 Employee Stock Purchase Plan. |
| August 16, 2024 | Date of stock sales to cover tax withholding obligations. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.